Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 6.62B P/E - EPS this Y -17.00% Ern Qtrly Grth -
Income -456M Forward P/E 14.01 EPS next Y 39.80% 50D Avg Chg -2.00%
Sales 4.5B PEG 15.36 EPS past 5Y - 200D Avg Chg 11.00%
Dividend N/A Price/Book 0.95 EPS next 5Y 1.50% 52W High Chg -14.00%
Recommedations 1.00 Quick Ratio 0.77 Shares Outstanding 351.90M 52W Low Chg 48.00%
Insider Own 88.50% ROA 0.96% Shares Float 40.96M Beta 0.46
Inst Own 11.74% ROE -6.50% Shares Shorted/Prior 2.20M/1.91M Price 18.91
Gross Margin 60.85% Profit Margin -10.15% Avg. Volume 494,900 Target Price 27.05
Oper. Margin 3.04% Earnings Date Jul 31 Volume 1,023,819 Change -2.27%
About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Corporation News
12/13/24 BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances
12/12/24 Bausch + Lomb Responds to Rumors of a Potential Sale
12/11/24 Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
11/22/24 Bausch & Lomb Corporation (BLCO)-A Bull Case Theory
11/14/24 Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
11/01/24 Bausch + Lomb Third Quarter 2024 Earnings: Beats Expectations
10/31/24 Bausch & Lomb Corp (BLCO) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
10/30/24 Bausch + Lomb Announces Third-Quarter 2024 Results
10/23/24 Bausch + Lomb price target raised to $23 from $20 at RBC Capital
10/14/24 Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
10/09/24 Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30
10/02/24 Bausch + Lomb price target raised to $19 from $17 at Evercore ISI
10/01/24 Bausch + Lomb Launches Opal™ Digital Marketplace in the United States
09/16/24 Bausch + Lomb explores sale amid parent company's debt woes - report
08/09/24 Bausch + Lomb Insider Ups Holding During Year
08/07/24 Insider Buying: CEO Brent Saunders Acquires Shares of Bausch & Lomb Corp
07/31/24 Bausch + Lomb Announces Second-Quarter 2024 Results
07/11/24 Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31
07/08/24 Millions of Americans Experience Dry Eye Symptoms, Yet New National Survey Shows Sufferers Struggle to Find Relief
06/17/24 Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress